<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) is the association of <z:mp ids='MP_0005048'>thrombosis</z:mp> and recurrent pregnancy loss and/or pregnancy morbidity with persistent <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPL) </plain></SENT>
<SENT sid="1" pm="."><plain>Increased complement activation has been implicated in the pathogenesis of APS in animal models </plain></SENT>
<SENT sid="2" pm="."><plain>It was our objective to evaluate complement activation in patients with aPL or <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="3" pm="."><plain>We measured complement activation products, fragments Bb and C3a-desArg by ELISA in 186 aPL/PAPS patients and 30 healthy controls </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with aPL had significantly increased levels of complement activation products </plain></SENT>
<SENT sid="5" pm="."><plain>Fragment Bb levels (mean, 95% CI); (thrombotic APS 0.54 units/ml, 0.31-0.83, obstetric APS 0.60 units/ml,0.39-1.02, isolated aPL 0.48 units/ml, 0.29-0.85, overall 0.39 units/ml, 0.33-0.47) and C3a-desArg levels (mean, 95% CI): (thrombotic APS 261 ng/ml, 219-311, obstetric APS 308 ng/ml, 243-391, isolated aPL 258 ng/ml, 193-337, overall 225 ng/ml, 202-251) were significantly higher compared to controls (fragment Bb 0.06 units/ml, 0.03-0.11, C3a-desArg 69 ng/ml, 50-92) </plain></SENT>
<SENT sid="6" pm="."><plain>There were correlations between Fragment Bb and C3a-desArg levels in <z:hpo ids='HP_0000001'>all</z:hpo> patients with aPL </plain></SENT>
<SENT sid="7" pm="."><plain>Receiver operator characteristic (ROC) analysis showed increased fragment Bb and C3a-desArg levels had strong associations with the presence of persistent <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (area under ROC: Bb 0.89, and C3a-desArg 0.90), dual and triple aPL positivity (Bb 0.71-0.82, C3a-desArg 0.71-0.80) but not with high titre anti-<z:chebi fb="0" ids="28494">cardiolipin</z:chebi> antibodies (Bb 0.62, C3a-desArg 0.65), or anti Î²2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> 1 antibodies (Bb 0.66, C3a-desArg 0.67) </plain></SENT>
<SENT sid="8" pm="."><plain>Complement activation is present in <z:hpo ids='HP_0000001'>all</z:hpo> patient groups within this large cohort of patients aPL </plain></SENT>
<SENT sid="9" pm="."><plain>This suggests it may have a major role in the pathogenesis of APS and merits further study </plain></SENT>
</text></document>